{"id":385817,"date":"2023-02-03T00:00:00","date_gmt":"2023-02-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/47037310-medtech-dialysis-access-treatment-devices-market-insights-europe-supplemental-2023\/"},"modified":"2026-06-04T23:04:29","modified_gmt":"2026-06-04T23:04:29","slug":"47037310-medtech-dialysis-access-treatment-devices-market-insights-europe-supplemental-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/47037310-medtech-dialysis-access-treatment-devices-market-insights-europe-supplemental-2023\/","title":{"rendered":"Dialysis Access Treatment Devices | Market Insights | Europe (Supplemental) | 2023"},"content":{"rendered":"<p>The\u00a0COVID-19\u00a0pandemic has had a negative impact on the European dialysis access treatment device market in 2020, and to some extent in 2021. Once the market stabilizes, the European dialysis access treatment device market will be primarily driven by the rising adoption of innovative technologies such as percutaneous\u00a0AVF, for dialysis creation, and\u00a0DCBs, for dialysis maintenance. The dynamic nature of the market, the launch of novel and innovative premium-price products backed by clinical data, and improvement in reimbursement will lead to\u00a0strong growth\u00a0through the remainder of forecast period. However, revenue growth will be limited to some extent due to increasing price competition and ongoing cost constraints in the region.<\/p>\n<p>This Medtech 360 Report provides high-level market metrics for dialysis access treatment devices in Europe, including country-level data for major countries and aggregate data for the rest of the Europe from 2019 through 2031.<\/p>\n","protected":false},"template":"","class_list":["post-385817","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-geography-europe","medtech-date-976"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/385817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/385817\/revisions"}],"predecessor-version":[{"id":387327,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/385817\/revisions\/387327"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=385817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}